Emcure Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) recently completed an inspection at its manufacturing facility in Sanand, Ahmedabad, Gujarat. The inspection, conducted from May 6 to May 15, 2026, resulted in the issuance of a Form 483 containing seven observations. The company clarified that the observations highlighted by the USFDA are procedural in nature.
Emcure Pharmaceuticals is actively addressing the observations to ensure compliance with regulations and plans to submit a comprehensive response within the specified timeframe. As per USFDA guidelines, companies typically have 15 days to respond to Form 483 observations. It is important to note that the issuance of a Form 483 does not signify a final determination regarding the facility’s compliance status.
In addition to the regulatory update, Emcure Pharmaceuticals reported a significant increase in net profit for the quarter, marking a 29% year-on-year growth. The company’s revenue from operations also saw a notable rise of 16.7% year-on-year, driven by growth in key markets. EBITDA witnessed a 19.2% increase, reaching Rs 479.5 crore, with EBITDA margins showing a slight improvement compared to the previous year.
Emcure Pharmaceuticals’ international business emerged as the primary growth driver, experiencing a 25.7% year-on-year revenue surge to Rs 1,493 crore. On the domestic front, sales grew by 5.2% to Rs 977 crore, although performance was somewhat affected by challenges in the Zuventus portfolio and ongoing organizational restructuring efforts. The company’s shares closed at Rs 1,702.30 apiece on the BSE after Friday’s trading session, reflecting a 1.73% increase from the previous close.
